Literature DB >> 28759252

Long Noncoding RNA Cancer Susceptibility Candidate 8 Suppresses the Proliferation of Bladder Cancer Cells via Regulating Glycolysis.

Renguang Hu1, Peng Zhong1, Lu Xiong2, Liangbin Duan1.   

Abstract

Increasing evidence highlights the critical regulatory role of long noncoding RNAs (lncRNAs) in carcinogenesis. Bladder cancer has become the most prevalent urologic malignancy, which is commonly diagnosed among adults. In this study, we showed that the lncRNA cancer susceptibility candidate 8 (CASC8) is significantly downregulated in bladder cancers and associated with the advanced stage of bladder cancer patients. Overexpression of CASC8 remarkably suppressed the bladder cancer cell proliferation. Mechanistically, we illustrated that CASC8 reduced the glycolysis of bladder cancer cells via interacting with the fibroblast growth factor receptor 1 (FGFR1). The binding of CASC8 with FGFR1 inhibits FGFR1-mediated lactate dehydrogenase A phosphorylation, which attenuates the conversion of pyruvate into lactate. Collectively, our findings uncovered the pivotal role of CASC8 in bladder tumorigenesis and suggested that CASC8 may function as a candidate biomarker for the diagnosis of bladder cancer.

Entities:  

Keywords:  CASC8; FGFR1; LDHA; bladder cancer; glycolysis

Mesh:

Substances:

Year:  2017        PMID: 28759252     DOI: 10.1089/dna.2017.3785

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  13 in total

1.  Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review.

Authors:  Guoming Su; Qili He; June Wang
Journal:  Front Physiol       Date:  2018-05-30       Impact factor: 4.566

2.  Significance of LncRNA CASC8 genetic polymorphisms on the tuberculosis susceptibility in Chinese population.

Authors:  Guoye Liu; Rui Xia; Qian Wang; Zhiqiang Wang; Binwu Ying; Hong Yan
Journal:  J Clin Lab Anal       Date:  2020-02-07       Impact factor: 2.352

3.  Association of lncRNA CCAT2 and CASC8 Gene Polymorphisms with Hepatocellular Carcinoma.

Authors:  Edie-Rosmin Wu; Ming-Ju Hsieh; Whei-Ling Chiang; Kuan-Chun Hsueh; Shun-Fa Yang; Shih-Chi Su
Journal:  Int J Environ Res Public Health       Date:  2019-08-08       Impact factor: 3.390

4.  High Cancer Susceptibility Candidate 8 Expression Is Associated With Poor Prognosis of Pancreatic Adenocarcinoma: Validated Analysis Based on Four Cancer Databases.

Authors:  Yingyi Wang; Yuemei Yang; Yanfeng Wang; Xiaoou Li; Yu Xiao; Wenze Wang
Journal:  Front Cell Dev Biol       Date:  2020-06-04

Review 5.  LncRNAs: The Regulator of Glucose and Lipid Metabolism in Tumor Cells.

Authors:  Wei Lu; Fenghua Cao; Shengjun Wang; Xiumei Sheng; Jie Ma
Journal:  Front Oncol       Date:  2019-11-26       Impact factor: 6.244

Review 6.  8q24.21 Locus: A Paradigm to Link Non-Coding RNAs, Genome Polymorphisms and Cancer.

Authors:  Claire Wilson; Aditi Kanhere
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

7.  Identification of a Novel Glycolysis-Related LncRNA Signature for Predicting Overall Survival in Patients With Bladder Cancer.

Authors:  Zhenming Zheng; Cong Lai; Wenshuang Li; Caixia Zhang; Kaiqun Ma; Yousheng Yao
Journal:  Front Genet       Date:  2021-08-19       Impact factor: 4.599

8.  Role of DiGeorge syndrome critical region gene 9, a long noncoding RNA, in gastric cancer.

Authors:  Chao Ni; Ping Yang; Junming Guo; Meng Ye
Journal:  Onco Targets Ther       Date:  2018-04-19       Impact factor: 4.147

9.  Construction of a Competitive Endogenous RNA Network for Pancreatic Adenocarcinoma Based on Weighted Gene Co-expression Network Analysis and a Prognosis Model.

Authors:  Jing Wang; Jinzhu Xiang; Xueling Li
Journal:  Front Bioeng Biotechnol       Date:  2020-05-28

Review 10.  Regulation of Glucose and Lipid Metabolism by Long Non-coding RNAs: Facts and Research Progress.

Authors:  Tie-Ning Zhang; Wei Wang; Ni Yang; Xin-Mei Huang; Chun-Feng Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-16       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.